• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Maraviroc: New Antiretroviral Drug Shows Efficacy and Safety

  • — 13 Mar, 2007
AudioMedica News
AudioMedica News
Maraviroc: New Antiretroviral Drug Shows Efficacy and Safety
Maraviroc: New Antiretroviral Drug Shows Efficacy and Safety
00:00 /
RSS Feed
Share
Link
Embed
Howard Mayer

Mark Wainberg

HOWARD MAYER, Pfizer Global Research, New London CT
MARK WAINBERG, McGill University, Montreal

Abstract Number: 104aLB, 104bLB, 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles February 25-28, 2007
In a population of treatment-experienced HIV-infected subjects, maraviroc plus optimised background antiretroviral therapy provided significantly superior virologic control and increases in CD4 cell counts compared with placebo plus optimized background therapy. There were no clinically relevant differences in the safety profiles between the maraviroc and the placebo treatment groups. These drugs do not attack the virus itself but rather block host cells’ CCR5 cell surface cytokine receptors that HIV interacts with to gain entry into the cell. At the Los Angeles conference Dan Keller heard about the studies from Howard Mayer and Mark Wainberg.

[audio:https://www.audiomedica.com/podcasting/global_health/070313howard_mayer.mp3]

You may also like...

  • Study on Longevity Genes And Aging Raises Prospects for Therapy Study on Longevity Genes And Aging Raises Prospects for Therapy 19 Apr, 2007
  • Ahmad Moolla Preparing for a healthy Olympics: lessons from the Hajj 23 May, 2012
  • Shiva Kumar India Aims For Universal Healthcare By 2020 14 Feb, 2011
  • Richard Oxborough New Insecticides Promise To Beat Mosquito Resistance In Africa 2 Jan, 2012
  • Previous story Integrase Inhibitor Raltegravir Doubles Antiviral Response Rate in Treatment Experienced HIV-Infected Patients Compared to Optimised Background Therapy Alone
  • Next story 6 Months Exclusive Breast Feeding for Mothers with HIV Lowers Transmission Rates
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic Lymphocytic…
    • Microbiome Diversity Key To Survival After Allogeneic…
    • New Front Line Standard for Older Patients with Chronic…
    • CT Screening Cuts Lung Cancer Deaths 24 Per Cent—Second…
    • Genomic-led AML Clinical Decision Making Within Seven Days
  • Home
  • Public Health
  • Maraviroc: New Antiretroviral Drug Shows Efficacy and Safety

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.